evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract
18112,GENE_SUMMARY,,"CD274 encodes programmed death ligand 1 (PD-L1), an inhibitory immune receptor ligand expressed by antigen presenting cells. Tumor cells commonly overexpress CD274 in order to evade the immune system.",,2017-01-09,,29126,CD274,CD274 molecule,False,ENST00000381577,NM_014143.3,B7H1,PD-L1,PDCD1L1,PDCD1LG1,PDL1,B7-H,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18113,GENE_BACKGROUND,,"The CD274 gene encodes programmed death ligand 1 (PD-L1), a member of a family of co-stimulatory immune receptor ligands. PD-L1 acts to inhibit an immune response by binding to the PD-1 cell surface receptor, which is expressed by T cells, B cells and natural killer cells (PMID: 17629517). PD-L1 allows tumor cells to evade the host immune system by suppressing the T cell response. Amplification or overexpression of PD-L1 has been identified in some tumor types and can be predictive of responses to immunotherapy (PMID: 22437870, 26918453, 28652380, 27620277), suggesting that PD-L1 functions as an oncogene. Individuals with tumors expressing PD-L1 should be considered for immune checkpoint therapy. Atezolizumab, a monoclonal antibody targeting PD-L1, is FDA approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma (PMID: 28424325) and metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy (PMID: 28611199). Pembrolizumab, an anti-PD-1 antibody, is considered first-line therapy for patients with non-small cell lung cancer and metastatic melanomas that express PD-L1, and may be efficacious in other tumors that express PD-L1 (PMID: 28806116). Nivolumab, an FDA-approved monoclonal antibody that targets PD-1, is also effective in tumors with high PD-L1 expression due to the blockade of the PD-1/PD-L1 interaction and activation of a robust immune response (PMID: 28806116).",,2017-09-01,,29126,CD274,CD274 molecule,False,ENST00000381577,NM_014143.3,B7H1,PD-L1,PDCD1L1,PDCD1LG1,PDL1,B7-H,False,28611199,U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-08-15T20:17:00,23,16,4534-4539,Weinstock C et al,doi: 10.1158/1078-0432.CCR-17-0540,,0001-08-15,,27620277,Genomic Amplification of &lt;i&gt;CD274&lt;/i&gt; (PD-L1) in Small-Cell Lung Cancer.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-03-01T20:17:00,23,5,1220-1226,George J et al,doi: 10.1158/1078-0432.CCR-16-1069,,2018-03-01T12:26:00,,26918453,CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.,Oncotarget,2018-03-15T20:16:00,7,11,12024-34,Straub M et al,doi: 10.18632/oncotarget.7593,,0001-03-15,,28424325,FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.,The oncologist,2018-06-01T20:17:00,22,6,743-749,Ning YM et al,doi: 10.1634/theoncologist.2017-0087,,2018-06-01T07:49:00,,28806116,Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018-10-20T20:17:00,35,30,3484-3515,Hanna N et al,doi: 10.1200/JCO.2017.74.6065,,0001-10-20,,17629517,Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.,Immunity,2018-07-01T20:07:00,27,True,111-22,Butte MJ et al,,,0001-07-01,,22437870,The blockade of immune checkpoints in cancer immunotherapy.,Nature reviews. Cancer,2018-03-22T20:12:00,12,4,252-64,Pardoll DM,doi: 10.1038/nrc3239,,0001-03-22,,28652380,Immune Escape in Breast Cancer During &lt;i&gt;In Situ&lt;/i&gt; to Invasive Carcinoma Transition.,Cancer discovery,2018-10-01T20:17:00,7,10,1098-1115,Gil Del Alcazar CR et al,doi: 10.1158/2159-8290.CD-17-0222,,2018-10-01T11:15:00,
